OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) – Opportunity Analysis and Forecasts to 2017

Publisher Name :
Date: 30-Sep-2013
No. of pages: 128

GlobalData has released its new Opportunity Analyzer report, “Nonalcoholic Steatohepatitis (NASH) – Opportunity Analysis and Forecasts to 2017”. The NASH market is currently deserted and awaits its first NASH-specific therapy. With novel mechanism of action awaiting approval such as: Genfit’s PPAR agonist, GFT505 and Intercept Pharmaceuticals/Dainippon Sumitomo Pharma’s FXR agonist, Obeticholic Acid. These compounds will race to be the first approved therapy thus claiming first in class.

Scope


  • Overview of NASH, including epidemiology, etiology, symptoms, diagnosis, pathology and disease management.

  • Analysis of the current and future market competition in the global NASH therapeutics market.

  • Pipeline analysis: comprehensive data split across Phase II/IIb, emerging trends and mechanisms of action under development, including: oral Proliferator Activated Receptor alpha, delta (PPARa,d) agonist, oral Farnesoid X Receptor (FXR) agonist, subcutaneous Lysyl Oxidase-Like 2 (LOXL2) inhibitor and subcutaneous Glucagon-like Peptide-1 (GLP-1) agonist.

  • Annualized NASH therapeutics market forecast, annual cost of therapy and treatment usage pattern data from 2012-2017.

  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

  • Key topics covered include strategic clinical and commercial benchmarking assessment of the pipeline and standard of care, market outlook, R&D strategies, and unmet needs for the NASH therapeutics market.


Reasons To Buy

Develop business strategies and perform superior market quantification analysis by:


  • Understanding the trends shaping and driving the global NASH Therapeutics market.

  • Understanding treatment preferences of physicians in disease state and across treatment flow.

  • Accessing market sizing, forecasts and quantified growth opportunities in the global NASH Therapeutics market till 2017.

  • Quantifying patient population in the global NASH Therapeutics market to better design product pricing & launch plans.

  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by

  • Performing benchmarking analysis and growth opportunities against currently marketed products.

  • Identifying market entry points based on safety, efficacy, and pricing parameters.

  • Assessing competitiveness of products in market by understanding the strength and weakness of current competition.

  • Develop and design your in-licensing and out-licensing strategies by

  • Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.

  • Assessing strength of pipeline based on first in class and lifecycle management of products.

  • Analyze the potential impact of novel oral therapies such as Genfit’s GFT505 on the NASH treatment paradigm.

  • Track drug sales in the global NASH Therapeutics market from 2012 to 2017.

  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

  • What’s the next big thing in the global NASH Therapeutics market landscape Identify, understand, and capitalize.

OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) – Opportunity Analysis and Forecasts to 2017

Table of Contents

1 Table of Contents 7
1.1 List of Tables 11
1.2 List of Figures 12

2 Introduction 13
2.1 Catalyst 13

3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 15
3.2 Symptoms 19

4 Epidemiology 21
4.1 Disease Background 21
4.2 Risk Factors and Comorbidities 22
4.2.1 Increased age is associated with a worsened disease progression, prognosis, and mortality 22
4.2.2 Being a male is an independent risk factor in morbidly obese NASH cases 23
4.2.3 Metabolic conditions, such as type 2 diabetes, considerably increase the risk of NASH 25
4.3 Global and Historical Trends 26
4.3.1 US 28
4.3.2 5EU 29
4.4 Forecast Methodology 31
4.4.1 Sources Used 33
4.4.2 Forecast Assumptions and Methods 35
4.4.3 Sources Not Used 38
4.5 Epidemiology Forecast of Nonalcoholic Steatohepatitis (2012-2022) 39
4.5.1 Total Prevalent Cases of Nonalcoholic Steatohepatitis 39
4.5.2 Age-Specific Prevalent Cases of Nonalcoholic Steatohepatitis 41
4.5.3 Sex-Specific Prevalent Cases of Nonalcoholic Steatohepatitis 44
4.5.4 Age-Standardized Prevalence of Nonalcoholic Steatohepatitis 45
4.6 Discussion 46
4.6.1 Conclusions on Epidemiological Trends 46
4.6.2 Limitations of the Analysis 47
4.6.3 Strengths of the Analysis 48

5 Current Treatment Options 49
5.1 Overview 49
5.2 Product Profiles - Major Off-Label Brands 52
5.2.1 Vitamin E (numerous generics) 52
5.2.2 Pioglitazone (Actos) 56

6 Unmet Needs Assessment and Opportunity Analysis 61
6.1 Overview 61
6.2 Unmet Needs Analysis 63
6.2.1 Lack of Approved Therapies 63
6.2.2 Identification of Biomarkers for Early Diagnosis and Endpoints 64
6.2.3 Physician Awareness Due to Understanding of Pathophysiology 65
6.3 Opportunity Analysis 65
6.3.1 Therapies with Targeted MOA to NASH 65
6.3.2 Better Models to Understand Drug Efficacy 65
6.3.3 Future Tool to Measure Fibrosis in NASH Patients 66

7 R&D Strategies 67
7.1 Overview 67
7.1.1 Understanding Multiple Factors of NASH 67
7.1.2 Potential for a Personalized Approach 68
7.2 Clinical Trial Design 69
7.2.1 Differences in Diagnosis, Monitoring, and Sensitive Imaging Techniques Are Needed 70
7.2.2 Patient Recruitment Issues 70
7.2.3 Appropriate Endpoints 71
7.2.4 Clinical Regulatory Guidelines 72

8 Pipeline Assessment 74
8.1 Overview 74
8.2 Promising Drugs in Clinical Development 75
8.2.1 GFT505 76
8.2.2 Obeticholic Acid (INT-747) 80
8.2.3 Simtuzumab (Formerly GS-6624) 84
8.2.4 Liraglutide (Victoza) 88
8.3 Innovative Early-Stage Approaches 92
8.3.1 Targeting Cytokines 93

9 Pipeline Valuation Analysis 95
9.1 Clinical Benchmark of Key Pipeline Drugs 95
9.2 Commercial Benchmark of Key Pipeline Drugs 98
9.3 Competitive Assessment 100
9.4 Top-Line Five-Year Forecast 101
9.4.1 US 105
9.4.2 5EU 106

10 Appendix 108
10.1 Bibliography 108
10.2 Abbreviations 116
10.3 Methodology 119
10.4 Forecasting Methodology 119
10.4.1 Diagnosed NASH Patients 119
10.4.2 Percent Drug-Treated Patients 120
10.4.3 Drugs Included in Each Therapeutic Class 120
10.4.4 Launch Dates 121
10.4.5 General Pricing Assumptions 121
10.4.6 Individual Off-Label Drug Assumptions 122
10.4.7 Pricing of Pipeline Agents 122
10.5 Physicians and Specialists Included in this Study 123
10.6 About the Authors 124
10.6.1 Author 124
10.6.2 Epidemiologist 125
10.6.3 Global Head of Healthcare 126
10.7 About GlobalData 127
10.8 Disclaimer 127

List of Tables

Table 1: Symptoms of NASH 19
Table 2: Risk Factors and Comorbidities for NASH 22
Table 3: Reported Prevalence of NASH in the US and 5EU 27
Table 4: Reported Prevalence of NAFLD in the US and 5EU 27
Table 5: 6MM, Sources of Prevalence Data Used in the NASH Epidemiological Forecast 32
Table 6: 6MM, Prevalent Cases of NASH, Ages ? 20 Years, Men and Women, N, Selected Years, 2012-2022 40
Table 7: 6MM, Prevalent Cases of NASH, By Age*, Men and Women, N (Row %), 2012 42
Table 8: 6MM, Prevalent Cases of NASH, Ages ? 20 Years, By Sex, N (Row %), 2012 44
Table 9: Off-Label Treatments for NASH 51
Table 10: Product Profile - Vitamin E 53
Table 11: Vitamin E SWOT Analysis in NASH, 2013 55
Table 12: Product Profile - Pioglitazone 57
Table 13: Pioglitazone SWOT Analysis in NASH, 2013 60
Table 14: Overall Unmet Needs in NASH - Current Level of Attainment 62
Table 15: Current Clinical Trial Design of Key Pipeline Drugs for NASH, 2013 73
Table 16: NASH - Mid-Late-Stage Pipeline, 2013 75
Table 17: Product Profile - GFT505 77
Table 18: GFT505 SWOT Analysis, 2013 79
Table 19: Product Profile - Obeticholic Acid (INT-747) 81
Table 20: Obeticholic Acid (INT-747) SWOT Analysis, 2013 83
Table 21: Product Profile - Simtuzumab 85
Table 22: Simtuzumab SWOT Analysis, 2013 87
Table 23: Product Profile - Liraglutide 89
Table 24: Liraglutide Safety Profile from the LEAD Program 90
Table 25: Liraglutide SWOT Analysis, 2013 91
Table 26: Early-Stage Pipeline Products in NASH, 2013 93
Table 27: Clinical Benchmark of Key Pipeline Drugs for NASH, 2013 97
Table 28: Commercial Benchmark of Key Pipeline Drugs for NASH, 2013 99
Table 29: Top-Line Sales Forecasts ($m) for NASH, 2012-2017 102
Table 30: Key Events Impacting Sales for NASH, 2017 103
Table 31: NASH Market: US and 5EU - Drivers and Barriers, 2012-2017 104
Table 32: Key Launch Dates 121

List of Figures

Figure 1: Two-Hit and Multiple-Hits Theories in NASH 16
Figure 2: Distinct-Hit Pathogenesis in NASH 18
Figure 3: Stages of Liver Disease 20
Figure 4: 5EU, Prevalence of NAFLD and Obesity, Ages ? 20 Years, Men and Women, % 30
Figure 5: 6MM, Prevalent Cases of NASH, Ages ? 20 Years, Men and Women, N, Selected Years, 2012-2022 40
Figure 6: 6MM, Prevalent Cases of NASH, By Age*, Men and Women, N, 2012 43
Figure 7: 6MM, Prevalent Cases of NASH, Ages ? 20 Years, By Sex, N, 2012 45
Figure 8: Liver Biopsy to Confirm NASH 50
Figure 9: Competitive Assessment of Mid-Stage Pipeline Agents in NASH, 2012-2017 76
Figure 10: Competitive Assessment of Mid-Stage Pipeline Agents in NASH, 2012-2017 100
Figure 11: Global Sales for NASH by Region, 2012-2017 103

  • China Commercial Vehicle Industry
    Commercial vehicle are usually large trucks, buses or vans used to transport people,  goods and material. China is one of the nations that contributes to over 50% of commercial vehicle production. The industry has grown in leaps and bounds over the couple of years. Even though the growth rates aren’t as impressive as two years [...]
  • The Prospective Market of Drug Eluting Stents
    Drug Eluting Stents are the recent development that’s are now being used frequently for curing narrowed coronary arteries. These stents help to keep the artery open and supply drugs at regular intervals preventing any further obstruction. The stents are usually small scaffolds of wire and are placed in the artery. This has been a welcome [...]
  • Anaesthesia Machine Industry is Flourishing due to an Extensive Customer Base with Therapeutic Needs
    The Anaesthesia Machine Industry comprises of the manufacturers and users of Anaesthesia Machines which are basically workstations or units that assist a person to administer Anaesthesia on the other. It includes plug & play Anaesthesia delivery units (ADUs). The industry also comprises of the various accessories like monitors and information systems and support services involved [...]
  • The Need for an Electric Cars Boosts The Lithium Sulfate Market
    Lithium is a highly demanded material. The popularity of this metal is primarily due to the characteristics of this metal and its compounds. Some of the characteristics of this material are that it has the highest electrochemical potential of all metals, a very high co-efficient of thermal expansion, acting as a viscosity modifier in melts, [...]
  • Tire Roller Industry
    Tire roller is one of the most popular equipment used in the construction industry. A tire roller offers multiple services from building highways, industrial sites, binder courses, wear courses and many more. Tire rollers come with different features like easy adjustment of tyres, flexible ballast, oscillating tires, etc. that facilitates in doing a particular work. [...]
    • The Oil Drilling Rig Industry
    • The Oil Drilling Rig Industry is characterized with a few typical work specific to this industry only. The work begins with the search for new oil basins or construction of wells. During this time the services of drilling contractors and se…

    • HER2-Negative Breast Cancer’s Therapeutic Market
    • HER2-Negative Breast Cancer is the most common form of cancer occurring in women. The long term survival of patients diagnosed with HER2-Negative Breast Cancer depends solely on its early detection as till now there is no medicine that can …

    • The Market of Plate Heat Exchanger
    • Plate heat exchanger is not only very useful but its also easy to maintain, its compact design makes it more efficient, the product is highly cost-efficient and also the materials of this product are easily available. There are some limitat…

    • The Industry of Binding Machines
    • Binding of books and papers is one of the most important aspect of buying and selling books and thus the demand of binding machines. There are different kinds of binding machines available in the market. The binding type determines the bind…

    • The Boom In Women Infertility Market
    • Infertility is an abnormality in the regular functioning of the human reproductive system. Anyone of male or female might be suffering from this issue. Infertility in woman is caused by either a genetical factor or factors such as aging or …

  • Orphan Diseases Therapeutics Market to 2018
    Published: 31-Dec-2011        Price: US 3500 Onwards        Pages: 0
    Report Summary Order Now With Pre-Publication Discount - GBI Research's new report will provide in depth analysis and expert insight into the "Orphan Diseases Therapeutics Market to 2018". The challenges in developing drugs for orphan indications are significant, but large pharmaceutical companies are showing increasing interest in the area and entering the market through strategic acquisitions and licensing agreements with smaller companies that have a strong research focus, as demonstrat......
  • Chronic Urticaria Or Hives Therapeutics - Pipeline Assessment and Market Forecasts to 2018
    Published: 01-Jan-2012        Price: US 3995 Onwards        Pages: 0
    GlobalData, the industry analysis specialist, has released its new report, “Chronic Urticaria Or Hives Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Chronic Urticaria Or Hives Therapeutics market. The report identifies the key trends shaping and driving the global Chronic Urticaria Or Hives Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging p......
  • Clostridium difficile (CDID) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
    Published: 01-Jan-2012        Price: US 3996 Onwards        Pages: 64
    GlobalData, the industry analysis specialist, has released its new report, “Clostridium difficile (CDID) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Clostridium difficile (CDID) Therapeutics market. The report identifies the key trends shaping and driving the global Clostridium difficile (CDID) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emer......
  • Polycythemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019
    Published: 01-Jan-2012        Price: US 3995 Onwards        Pages: 0
    GlobalData, the industry analysis specialist, has released its new report, “Polycythemia Vera Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Polycythemia Therapeutics market. The report identifies the key trends shaping and driving the global Polycythemia Vera Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging pla......
  • Hepatitis C Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020
    Published: 01-Jan-2012        Price: US 6995 Onwards        Pages: 0
    GlobalData, the industry analysis specialist, has released its new report, “Hepatitis C Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the global Hepatitis C Therapeutics market. The report provides comprehensive information on Hepatitis C Therapeutics, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global Hepatitis C Therapeutics market. It analyses t......
  • Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014
    Published: 08-Jan-2012        Price: US 3500 Onwards        Pages: 159
    GBI Research, the leading business intelligence provider, has released its latest report, Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major musculoskeletal disorders, including rheumatoid......
  • Hepatic Encephalopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2019
    Published: 01-Feb-2012        Price: US 3995 Onwards        Pages: 0
    GlobalData, the industry analysis specialist, has released its new report, “Hepatic Encephalopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Hepatic Encephalopathy Therapeutics market. The report identifies the key trends shaping and driving the global Hepatic Encephalopathy Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expec......
  • Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017
    Published: 21-Feb-2012        Price: US 3500 Onwards        Pages: 0
    Immunosuppressants holds a 64% Market Share of the Immunomodulators Market with More Products in the Pipeline than Immunostimulants This report provides insight about immunomodulators sales forecasts until 2017. Immunomodulators markets in the key geographies of the US, Europe and other relevant regions are also covered in the report, as are immunomodulators R&D pipelines. The report provides in-depth analysis and market forecasts of the major drug classe......
  • Portal Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2019
    Published: 29-Feb-2012        Price: US 3995 Onwards        Pages: 57
    Portal Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, "Portal Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Portal Hypertension Therapeutics market. The report identifies the key trends shaping and driving the global Portal Hypertension Therapeutics ma......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs